Deze pagina is automatisch vertaald en de nauwkeurigheid van de vertaling kan niet worden gegarandeerd. Raadpleeg de Engelse versie voor een brontekst.

Enfortumab Vedotin in Combination With Pembrolizumab vs. Concurrent Chemoradiotherapy (cCRT) in People With Muscle Invasive Bladder Cancer (EV-309)

27 oktober 2026 bijgewerkt door: Astellas Pharma Global Development, Inc.

A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY TO EVALUATE ENFORTUMAB VEDOTIN IN COMBINATION WITH PEMBROLIZUMAB IN ADULT PARTICIPANTS WITH MUSCLE-INVASIVE BLADDER CANCER WHO ARE INELIGIBLE FOR OR HAVE ELECTED NOT TO UNDERGO CYSTECTOMY

This study is being done to see how well two drugs (enfortumab vedotin and pembrolizumab) work together as a bladder preservation approach to treat patients with muscle invasive bladder cancer. The study will compare these drugs to concurrent chemoradiotherapy that is usually used to treat this cancer (standard of care). The study will enroll patients with muscle-invasive bladder cancer (MIBC) who have cancer that has not spread outside the bladder.

Studie Overzicht

Gedetailleerde beschrijving

This study is being conducted to evaluate the combination of enfortumab vedotin + pembrolizumab versus standard of care concurrent chemoradiotherapy, in subjects with previously untreated muscle invasive bladder cancer.

Enfortumab vedotin may be administered for up to 9 cycles or a protocol defined reason for study discontinuation occurs, whichever is first. Pembrolizumab may be administered for a maximum of 17 cycles (3-week cycles) or a protocol-defined reason for study discontinuation occurs, whichever is first. Concurrent chemoradiotherapy may be administered for a maximum of 6.5 weeks.

Studietype

Ingrijpend

Inschrijving (Geschat)

390

Fase

  • Fase 3

Contacten en locaties

In dit gedeelte vindt u de contactgegevens van degenen die het onderzoek uitvoeren en informatie over waar dit onderzoek wordt uitgevoerd.

Studiecontact

Studie Locaties

    • Quebec
      • Chicoutimi, Quebec, Canada
        • Werving
        • Site CA01194
      • Montreal, Quebec, Canada
        • Werving
        • Site CA01071
      • Montreal, Quebec, Canada
        • Werving
        • Site CA01052
      • Kaohsiung City, Taiwan
        • Werving
        • Site TW01117
    • Arkansas
      • Little Rock, Arkansas, Verenigde Staten, 72211
        • Werving
        • Arkansas Urology
    • California
      • Santa Barbara, California, Verenigde Staten, 93105
        • Werving
        • Samsun Clinic - Ridley-Tree Cancer Center
    • Colorado
      • Aurora, Colorado, Verenigde Staten, 80012
        • Werving
        • Rocky Mountain Cancer Center
    • Delaware
      • Newark, Delaware, Verenigde Staten, 19713
        • Werving
        • Medical Oncology Hematology Consultants
    • Illinois
      • Hinsdale, Illinois, Verenigde Staten, 60521
        • Werving
        • Hope and Healing Clinical Research LLC
      • New Lenox, Illinois, Verenigde Staten, 60451
        • Werving
        • Hope and Healing Clinical Research LLC
      • Niles, Illinois, Verenigde Staten, 60714
        • Werving
        • Illinois Cancer Specialists
    • Indiana
      • Fort Wayne, Indiana, Verenigde Staten, 46825
        • Werving
        • Fort Wayne Medical Oncology and Hematology
    • Michigan
      • Royal Oak, Michigan, Verenigde Staten, 48073
        • Werving
        • Comprehensive Urology
    • Missouri
      • Columbia, Missouri, Verenigde Staten, 65201
        • Werving
        • Missouri Cancer Associates
      • St Louis, Missouri, Verenigde Staten, 63110
        • Werving
        • Siteman Cancer Center
    • Nevada
      • Las Vegas, Nevada, Verenigde Staten, 89106
        • Werving
        • Comprehensive Cancer Centers of Nevada - Southwest
    • New York
      • New York, New York, Verenigde Staten, 10029
        • Werving
        • Icahn School of Medicine at Mount Sinai
    • Ohio
      • Fairfield, Ohio, Verenigde Staten, 45014
        • Werving
        • Oncology Hematology Care Clinical Trials, LLC
    • Oregon
      • Eugene, Oregon, Verenigde Staten, 97401
        • Werving
        • Williamette Valley Cancer Institute and Research Center
      • Tigard, Oregon, Verenigde Staten, 97223
        • Werving
        • Compass Oncology - West
    • Tennessee
      • Nashville, Tennessee, Verenigde Staten, 37203
        • Werving
        • SCRI Oncology Partners
    • Texas
      • Austin, Texas, Verenigde Staten, 78705
        • Werving
        • Texas Oncology
      • Tyler, Texas, Verenigde Staten, 75702
        • Werving
        • Texas Oncology - Northeast Texas
    • Virginia
      • Charlottesville, Virginia, Verenigde Staten, 22903
        • Werving
        • University of Virginia Comprehensive Cancer Center
      • Norfolk, Virginia, Verenigde Staten, 23502
        • Werving
        • Virginia Oncology Associates
      • Daegu, Zuid -Korea
        • Werving
        • Site KR01113
      • Seongnam-si, Zuid -Korea
        • Werving
        • Site KR01063
      • Seoul, Zuid -Korea
        • Werving
        • Site KR01065
      • Seoul, Zuid -Korea
        • Werving
        • Site KR01084

Deelname Criteria

Onderzoekers zoeken naar mensen die aan een bepaalde beschrijving voldoen, de zogenaamde geschiktheidscriteria. Enkele voorbeelden van deze criteria zijn iemands algemene gezondheidstoestand of eerdere behandelingen.

Geschiktheidscriteria

Leeftijden die in aanmerking komen voor studie

18 jaar en ouder (Volwassen, Oudere volwassene)

Accepteert gezonde vrijwilligers

Nee

Geslachten die in aanmerking komen voor studie

Allemaal

Beschrijving

Inclusion Criteria:

  • Has histologically confirmed initial diagnosis of muscle-invasive bladder cancer (MIBC) with predominant urothelial histology staged cT2-T4aN0M0
  • Tissue comprising muscle-invasive urothelial cancer must be submitted for clinical staging at baseline
  • Eligible for and agree to receive chemoradiotherapy and one of the protocol-specified radiosensitizing chemotherapy regimens
  • Fit for systemic therapy and elect bladder preservation, including participants who are ineligible for or have elected not to undergo cystectomy
  • Has Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2

Exclusion Criteria:

  • Advanced or metastatic disease (N+, M1), non-urothelial carcinoma, diffuse or multifocal CIS, urothelial carcinoma or histological variant at any site outside the urinary bladder within previous 24 months prior to randomization except Ta/T1/CIS of the upper urinary tract including renal pelvis and ureter if the participant had undergone complete nephrectomy
  • Has received any prior systemic treatment, chemoradiation, and/or radiation for MIBC or NMIBC
  • Prior pelvic radiation for any reason
  • Inadequate bladder function
  • Other active malignancies within 3 years prior to randomization
  • Previously treated with enfortumab vedotin or other MMAE-based antibody-drug conjugates (ADCs)
  • Previously treated with a PD(L)-1 inhibitor, defined as a PD-1 inhibitor or PD-L1 inhibitor
  • Uncontrolled diabetes
  • Currently receiving systemic antimicrobial treatment for active infection (viral, bacterial, or fungal) at the time of randomization. Routine antimicrobial prophylaxis is permitted
  • Known active hepatitis B, active hepatitis C, or human immunodeficiency virus (HIV) infection
  • Received major surgery (defined as requiring general anesthesia and >24 hour inpatient hospitalization) within 4 weeks prior to randomization
  • Known severe (≥ Grade 3) hypersensitivity to any enfortumab vedotin excipient contained in the drug formulation of enfortumab vedotin
  • Known genetic disorders associated with radiosensitivity (eg, ataxia telangiectasia, Nijmegen breakage syndrome, Fanconi syndrome)
  • Active keratitis or corneal ulcerations
  • History of autoimmune disease that has required systemic treatment in the past 2 years
  • History of idiopathic pulmonary fibrosis, organizing pneumonia, drug induced pneumonitis, idiopathic pneumonitis, or evidence of active pneumonitis on screening chest computed tomography (CT) scan
  • Prior allogeneic stem cell or solid organ transplant
  • Received a live attenuated vaccine within 30 days prior to randomization

Studie plan

Dit gedeelte bevat details van het studieplan, inclusief hoe de studie is opgezet en wat de studie meet.

Hoe is de studie opgezet?

Ontwerpdetails

  • Primair doel: Behandeling
  • Toewijzing: Gerandomiseerd
  • Interventioneel model: Parallelle opdracht
  • Masker: Geen (open label)

Wapens en interventies

Deelnemersgroep / Arm
Interventie / Behandeling
Experimenteel: Arm A

Enfortumab vedotin + pembrolizumab (EV + P)

Enfortumab vedotin administered as an IV infusion on Days 1 and 8 of every 3-week cycle up to cycle 9.

Andere namen:
  • • Padcev
  • • ASG-22CE
  • • ASG-22Me

IV infusion on Day 1 of every 3-week cycle up to cycle 17.

Andere namen:
  • Keytruda
Actieve vergelijker: Arm B

Concurrent Chemoradiotherapy (cCRT)

64 Gy in 32 fractions over 6.5 weeks administered to the participant's bladder only or the bladder and prophylactically to pelvic nodes.

55 Gy in 20 fractions over 4 weeks administered to the participant's bladder only.

40 mg of cisplatin per meter squared of body surface area, administered once weekly via IV infusion during radiation OR 20 mg of cisplatin per meter squared of body surface area per day on Days 1 and 2 weekly via IV infusion during radiation.

500 mg per meter squared of body surface area per day on Days 1-5 (week 1) and Days 22 26 (week 3) administered as continuous IV infusion during radiation in combination with mitomycin C.

Andere namen:
  • • 5-Fluorouracil
  • • 5-FU

12 mg per meter squared of body surface area administered as an IV bolus on Day 1 during radiation in combination with fluorouracil.

Andere namen:
  • • MMC

100 mg per meter squared of body surface area administered once weekly via IV infusion during radiation OR 27 mg per meter squared of body surface area administered twice weekly via IV infusion during radiation

Wat meet het onderzoek?

Primaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Bladder-intact Event Free Survival (BI-EFS) by Blinded Independent Central Review (BICR)
Tijdsspanne: Up to approximately 45.5 months

BI-EFS is defined as the time from randomization to any of the following events: histologically confirmed persistent or residual MIBC post-treatment confirmed by BICR, histologically confirmed recurrent MIBC by BICR, disease progression by BICR, cystectomy, or death from any cause.

Up to approximately 45.5 months
Overall Survival (OS)
Tijdsspanne: Up to approximately 60 months

Time from randomization to death due to any cause.

Up to approximately 60 months

Secundaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Bladder-intact Event Free Survival (BI-EFS) by Investigator
Tijdsspanne: Up to approximately 45.5 months

BI-EFS is defined as the time from randomization to any of the following events: histologically confirmed persistent or residual MIBC post-treatment, histologically confirmed recurrent MIBC, disease progression, cystectomy, or death from any cause.

Up to approximately 45.5 months
Complete clinical response (cCR) rate by Blinded Independent Central Review (BICR) and Investigator
Tijdsspanne: Up to approximately 60 months

cCR is defined as no radiographic evidence of residual or metastatic disease on imaging, negative cystoscopy, negative pathology except for low-grade Ta, and negative urine cytology.

Up to approximately 60 months
Metastasis-Free Survival (MFS) by Blinded Independent Central Review (BICR) and Investigator
Tijdsspanne: Up to approximately 60 months]

Time from randomization to radiologically or pathologically confirmed distant metastasis, or death due to any cause, whichever occurs first.

Up to approximately 60 months]
Time to Cystectomy
Tijdsspanne: Up to approximately 60 months

The time from randomization to cystectomy.

Up to approximately 60 months
Disease Free Survival (DFS) by Blinded Independent Central Review (BICR) and Investigator
Tijdsspanne: Up to approximately 60 months

The time from cCR to local recurrence or distant metastases, a second primary bladder cancer, or death due to any cause, whichever occurs first.

Up to approximately 60 months
Cystectomy Free Survival (CFS)
Tijdsspanne: Up to approximately 60 months

The time from randomization to cystectomy or death due to any cause, whichever occurs first.

Up to approximately 60 months
Number of Participants with Treatment Emergent Adverse Event (TEAE)
Tijdsspanne: From start of study treatment up to 30 days after last dose of study drug (approximately up to 1.1 years)

An AE is any untoward medical occurrence in a participant who receives a study treatment without regard to possibility of causal relationship. Treatment-emergent are events between the first dose of study treatment and up to 30 days after the last dose that were absent before treatment or that worsened relative to pretreatment state.

From start of study treatment up to 30 days after last dose of study drug (approximately up to 1.1 years)
Number of Participants with Serious TEAEs
Tijdsspanne: From start of treatment up to 90 days after the last dose of study treatment (approximately up to 1.3 years)

An SAE is any AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life threatening experience (immediate risk of dying); persistent or significant disability/ incapacity; congenital anomaly. Treatment-emergent are events between first dose of study drug and up to 90 days after last dose that were absent before treatment or that worsened relative to pretreatment state.

From start of treatment up to 90 days after the last dose of study treatment (approximately up to 1.3 years)

Medewerkers en onderzoekers

Hier vindt u mensen en organisaties die betrokken zijn bij dit onderzoek.

Medewerkers

Onderzoekers

  • Studie directeur: Zejing Wang, MD/PhD, Pfizer

Publicaties en nuttige links

De persoon die verantwoordelijk is voor het invoeren van informatie over het onderzoek stelt deze publicaties vrijwillig ter beschikking. Dit kan gaan over alles wat met het onderzoek te maken heeft.

Studie record data

Deze datums volgen de voortgang van het onderzoeksdossier en de samenvatting van de ingediende resultaten bij ClinicalTrials.gov. Studieverslagen en gerapporteerde resultaten worden beoordeeld door de National Library of Medicine (NLM) om er zeker van te zijn dat ze voldoen aan specifieke kwaliteitscontrolenormen voordat ze op de openbare website worden geplaatst.

Bestudeer belangrijke data

Studie start (Werkelijk)

11 mei 2026

Primaire voltooiing (Geschat)

31 maart 2030

Studie voltooiing (Geschat)

29 februari 2032

Studieregistratiedata

Eerst ingediend

29 april 2026

Eerst ingediend dat voldeed aan de QC-criteria

29 april 2026

Eerst geplaatst (Werkelijk)

4 mei 2026

Updates van studierecords

Laatste update geplaatst (Werkelijk)

28 oktober 2026

Laatste update ingediend die voldeed aan QC-criteria

27 oktober 2026

Laatst geverifieerd

1 oktober 2026

Meer informatie

Termen gerelateerd aan deze studie

Andere studie-ID-nummers

  • C5701009
  • EV-309 (Andere identificatie: Alias Study Number)
  • 2026-525612-34-00 (Ctis)

Plan Individuele Deelnemersgegevens (IPD)

Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?

ONBESLIST

Beschrijving IPD-plan

Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.

Informatie over medicijnen en apparaten, studiedocumenten

Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel

Ja

Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct

Nee

Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .

Abonneren